Skip to content
DataLookout
Menu

BALISTANCT06793332

BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jan 31, 2026 to Dec 31, 2026 Show 5 more changesShow less
    • Start date: Dec 17, 2024 to Feb 5, 2025
    • Eligibility criteria expanded, about 21 words
    • Study completion pushed from Jan 31, 2027 to May 31, 2027
    • Secondary endpoints: details revised at 3 of 3 entries
    • Publications: details revised at 4 of 4 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Intracranial objective response rate (CNS ORR)
Timeframe: 22 months(Up to approximately 12 weeks after the last patient's enrollment)

Secondary (3)

Intracranial clinical benefit rate (CNS CBR)
Progression-Free Survival (PFS)
Overall Survival (OS)

Arms and interventions

Ivonescimab combined with TROP2 ADCExperimental

Drugs: Ivonescimab Combined With TROP2 ADC

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer centerShanghai, Shanghai Municipality, China